Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999
Business Overview: Neurocrine is engaged in the discovery and development of prescription drugs for central nervous and immune system disorders. The Company has not generated product sales revenue and relies on strategic alliances, milestone payments, and public offerings to fund operations. As of the reporting date, the Company had five compounds in clinical development.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1999 | Balance Sheet (Sep 30, 1999) |
|---|---|---|---|
| Total Revenues | $5,231 | $12,592 | -- |
| Net Loss | $(4,407) | $(13,133) | -- |
| Loss Per Share (Basic & Diluted) | $(0.23) | $(0.69) | -- |
| Research & Development Expenses | $8,331 | $21,893 | -- |
| Cash and Cash Equivalents | -- | -- | $7,591 |
| Short-term Investments | -- | -- | $40,946 |
| Total Current Assets | -- | -- | $54,232 |
| Total Current Liabilities | -- | -- | $5,000 |
| Long-term Debt | -- | -- | $349 |
| Cumulative Deficit | -- | -- | $(37,983) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased to $5.2 million for the quarter (from $5.1 million in 1998) and $12.6 million for the nine-month period (from $11.5 million in 1998). Growth was driven by new collaborations with Wyeth-Ayerst and Janssen Pharmaceutica, including milestone payments.
- Expense Increases: Research and development expenses rose significantly to $8.3 million for the quarter (from $6.4 million) and $21.9 million for the nine months (from $15.5 million), reflecting increased scientific personnel and clinical trial costs.
- Net Loss: Net loss for the quarter increased to $4.4 million (from $4.0 million). However, the nine-month net loss decreased slightly to $13.1 million (from $13.2 million) due to a reduction in non-cash charges related to the equity method investment in Neuroscience Pharma, Inc. (NPI) and the absence of a $4.9 million write-off of in-process R&D that occurred in 1998.
- Liquidity: Cash and short-term investments declined to $48.5 million from $62.7 million at year-end 1998, reflecting the burn rate associated with advancing clinical programs.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur future net losses as operating expenses increase with clinical development. The Company believes existing capital resources, combined with interest income and future alliance payments, will be sufficient to fund operations through 2001.
- Revenue Volatility: Revenues are derived from funded research and milestone achievements, leading to substantial fluctuations between periods. Results of one period are not predictive of future periods.
- Year 2000 Compliance: The Company is Year 2000 compliant with an incremental cost of approximately $175,000. Contingency plans are in place for potential third-party failures.
- Risks: Key risks include the failure of product candidates in clinical trials, inability to secure regulatory approvals, dependence on third-party collaborators for funding, and potential intellectual property disputes.
- Corporate Changes: Harry F. Hixson, Jr. is resigning from the Board of Directors effective December 31, 1999.
Investor Verification Checklist
- Verify the status and payment terms of the strategic alliances with Wyeth-Ayerst and Janssen Pharmaceutica.
- Confirm the progress of the five compounds currently in clinical development.
- Assess the sufficiency of the $48.5 million in liquid assets to sustain operations through 2001 given the current burn rate.
- Review the terms of the floating rate note payable (prime + 0.25%) and its impact on future interest expenses.
- Monitor the timeline for replacing the resigning Board member.